Copyright © 2024 Research Nester. All Rights Reserved
Hepatitis B Treatment Market size was over USD 88.71 billion in 2023 and is likely to reach USD 155.27 billion by the end of 2036, growing at around 4.4% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of hepatitis B treatment is assessed at USD 91.83 billion.
The growth of the hepatitis B treatment market can be attributed primarily to the growing number of individuals who are infected by the hepatitis B virus, along with the need amongst the individuals to cure the viral infection.
Hepatitis is referred to as an inflammatory condition of the liver and is commonly caused by a hepatitis virus. The most common hepatotropic viruses that cause hepatitis are hepatitis A, B, C, D, and E. Hepatitis B is caused by Hepatitis B virus (HBV) which belongs to the viral family Hepadnaviridae. Viral hepatitis B infections are diagnosed by the use of virus testing diagnostic kits, whereas for non-viral infections, blood tests, liver ultrasound or liver biopsy tests are performed. Recently, with the advancements in medical sciences, rapid testing kits are also being used widely by medical practitioners for the detection of the disease. The treatment of hepatitis B is done by the use of the hepatitis B vaccine or through anti-viral drugs. Though, several players are still in search of developing a new cure for hepatitis B, and few of them are in the development of new drugs and medicines for hepatitis B, as the treatment developed for hepatitis B doesn’t totally eradicate the virus from the human body. Hepatitis B is transmitted commonly through direct contact with infected blood, especially during unsterile healthcare practices, or while giving birth to the newborn by the mother, who is a hepatitis B carrier. Hepatitis B is also transmitted through unprotected sexual intercourse or contact with bodily fluids. Hepatitis B infection in human beings can be either acute or chronic. The United States Food and Drug Administration (FDA) has approved eight different treatment options for the treatment of chronic hepatitis B. These include treatment with tenofovir alafenamide, adefovir, entecavir, pegylated interferon, tenofovir disoproxil, telbivudine, alpha-interferon, and lamivudine.
Growth Drivers
Challenges
|
2023 |
|
|
Forecast Year |
2024–2036 |
|
CAGR |
4.4% |
|
Base Year Market Size (2023) |
USD 88.71 billion |
|
Forecast Year Market Size (2036) |
USD 155.27 billion |
|
Regional Scope |
|
The hepatitis B treatment market is thriving on account of the growing need for a drug that can completely cure the virus infection, backed by the growing incidences of chronic hepatitis B infection globally, along with the growing awareness amongst individuals for the treatment of the disease. According to the statistics by the World Health Organization (WHO), around 240 million people globally are infected with chronic hepatitis B virus. Moreover, the statistics also stated that a cumulative 20 million deaths are anticipated to occur between 2015 and 2030. Further, the growing concern for liver cancer globally is also anticipated to contribute to the market growth in the coming years. The hepatitis B treatment market is segmented by product type into hepatitis B vaccine, and anti-viral drugs. The anti-viral drugs segment is further bifurcated into tenofovir (VIREAD), lamivudine (EPIVIR), entecavir (BARACLUDE), telbivudine (TYZEKA), and adefovir (HEPSERA). Among these segments, the tenofovir (VIREAD) segment is projected to hold a significant market share by the end of 2021. Two combinations of tenofovir are used widely for the treatment of chronic hepatitis B, namely tenofovir disoproxil fumarate (chemical formula: C19H30N5O10P; sold under the trade name VIREAD, developed by Gilead Sciences, Inc.), and tenofovir alafenamide (chemical formula: C21H29N6O5P; sold under the brand name VEMLIDY, developed by Gilead Sciences, Inc.). These anti-viral drugs are used in combination with other antiretrovirals for the treatment of hepatitis B and are listed on the list of essential medicines of the World Health Organization.
Impact of COVID-19 on the Global Hepatitis B Treatment Market
The coronavirus pandemic, which has impacted businesses worldwide, also had its impact on the hepatitis B treatment market. Owing to the COVID-19 pandemic, drug manufacturing companies have shifted their focus on the development of a novel vaccine for the prevention and treatment of the SARS-CoV2 virus. Furthermore, as the number of patients visiting the hospitals for the treatment of hepatitis B was very less, those companies who were into the phase of the clinical trials of their vaccine subjects, couldn’t continue with their research process, which further impacted the progress of research in the development of the novel drug. However, the operators operating in the development of the novel drug for the cure of hepatitis B, are anticipating that over the next few months, as the pandemic situation comes under control, the process for the development of novel drug would significantly be paced up, which in turn would contribute to the growth of the global hepatitis B treatment market.
Our in-depth analysis of the global hepatitis B treatment market includes the following segments:
|
Product |
|
|
Therapy |
|
|
Route of Administration |
|
|
Distribution Channel |
|
On the basis of regional analysis, the hepatitis B treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa regions.
Among the market in these regions, the Asia Pacific market is projected to hold the largest market share by the end of 2029 owing to the increasing prevalence of the viral disease in nations, such as China, Mongolia, Korea, Vietnam, and others, along with the growing need of the nations to find a cure for the viral disease. Alternatively, the hepatitis B treatment market in North America is projected to grow with the highest CAGR during the forecast period owing to the presence of several key players in the region who are increasingly focusing on developing novel therapies and drugs for the treatment of hepatitis B.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?